Attention Investors: Note: The depositories (CDSL/NSDL), in coordination with SEBI, have upgraded their investor mobile applications to provide a consolidated view of investors’ holdings in securities markets. CDSL: MyEasiApp | NSDL: Speede App Beware of fraudulent Calls, SMS, Emails, WhatsApp & Telegram messages assuring high returns and / or enticing you to invest money in the name of Aditya Birla Money by installing fake App from spurious links. You can download our Elevate App only from Google Play Store or Apple App Store or login to Elevate Web portal. Click Here to know more.
Experience finance made simple on the new ABCD app!
Scan to Download the App
One stop solution for all stock market enthusiasts
Whatsapp us!! We are Available.
Send HI on 8828800038
For Broking services
Call Toll Free Number :
1800-270-7000
( Mon - Fri: 9AM - 11PM )
( Sat & Sun: 9AM - 09PM )
Call N Trade
Call :
1800-108-9999
( 9AM to 11:30PM /11:55PM )
Acquire & service self-trading online & offline clients. Archive large-scale business success with the entire product range offered by us.
Earn while you refer client. No need to set up your own infrastructure.
Join our referral program, earn rewards when friends and family open accounts & transact. Spread the word, multiply your earnings!
Join the Entrepreneurial Tribe!
Aditya Birla Money Limited
Symbol : HALEOSLABS | BSE Code : 540679 | Sector : PHARMACEUTICALS - INDIAN - BULK DRUGS & FORMLN
Market Cap (₹ Cr.)
Turnover (₹ Cr.)
04/04/2026 BSE 45.20(3.61)Close Price: ₹ 1,299.00 Volume: 1.00
04/04/2026 BSE 54.40(4.54)Close Price: ₹ 1,253.80 Volume: 1.00
04/04/2026 BSE -50.60(-4.05)Close Price: ₹ 1,199.40 Volume: 17.00
04/04/2026 BSE 12.30(0.99)Close Price: ₹ 1,250.00 Volume: 10,001.00
04/04/2026 BSE -57.60(-4.45)Close Price: ₹ 1,237.70 Volume: 108.00
No Data Available
Net profit of Haleos Labs rose 21.02% to Rs 6.62 crore in the quarter ended December 2025 as against Rs 5.47 crore during the previous quarter ended December 2024. Sales rose 12.03% to Rs 94.78 crore in the quarter ended December 2025 as against Rs 84.60 crore during the previous quarter ended December 2024.
Haleos Labs consolidated net profit rises 21.02% in the December 2025 quarter
Haleos labs to convene board meeting
SMS Lifesciences India consolidated net profit rises 30.62% in the September 2025 quarter
In Cr.
SMS Lifesciences India Limited was incorporated originally as 'Potluri Real Estate Private Limited' on May 31, 2006. The Company's name was changed to 'Potluri Packaging Industries Private Limited' on 6 November, 2013 and again changed to 'SMS Lifesciences India Private Limited on 4 August, 2014 to undertake the activities related pharma sector. The Company became a wholly owned subsidiary Company of SMS Pharmaceuticals Limited w.e.f. 01.04.2016 and subsequently got converted into a Public Limited w.e.f. 22 June, 2016.The Company is engaged in the business of manufacturing and export of Active Pharma Ingredients(APIs) and their intermediates. The Company is having manufacturing facilities at Kazipally and Jeedimetla, Hyderabad with an installed capacity of 65 KL. What started off as a single facility - single product manufacturing company in 1990 grew to be a multi-location group having products spread across an array of therapeutic segments. SMS Group was given the export house status in the year 1997-98.Having three multi product facilities in operation and a research centre, the Company executed contract manufacturing and research assignment for global customer base. The Scheme of Arrangement between SMS Pharmaceuticals Limited with the Company was implemented in 2016-17. Pursuant to the Scheme, the Semi Regulated facilities i.e Unit No. I, IV and V along with premises situated at Industrial Estate, Sanathnagar, Hyderabad; Industrial Development Area, Jeedimetla, Hyderabad; Premises bearing Flat No.417, Nilgiri, Aditya Enclave, Ameerpet, Hyderabad; vacant land admeasuring Ac 19.00 cents situated at Pharma City, Parawada, Visakhapatnam and Investments relating to Semi Regulated Units of SMS Pharmaceuticals Limited got demerged into the Company and the said Scheme of Demerger was given effect on May 17, 2017. The Company allotted 30,23,287 Equity Shares of Rs. 10 each to the shareholders of SMS Pharmaceuticals Limited on 27 June, 2017 in pursuance of Demerg